Wound News and Research

RSS

Tregs to set the pace of recovery after serious lung injury

After more than 50 experiments in mice, medical scientists at Johns Hopkins have mapped out the basic steps taken by a particular set of white blood cells in setting the pace of recovery after serious lung injury.

22 Sep 2009

Mathematical model of an ischemic wound

Scientists expect a new mathematical model of chronic wound healing could replace intuition with clear guidance on how to test treatment strategies in tackling a major public-health problem.

22 Sep 2009

Differences between two types of integrins

The adhesion of cells to the various components of their environment is mediated mainly by molecules known as integrins. Two integrins, α5β1 and αvβ3, mediate adhesion with fibronectin, which is present in the extracellular matrix. But why are 2 molecules involved in the adhesion to a single extracellular component? An article published on-line in Proceedings of the National Academy of Sciences (PNAS), whose main author is Pere Roca-Cusachs, an IBEC researcher, offers the first experimental answer to this question.

21 Sep 2009

KCI to conduct discussion on limb surgeries and amputations

Kinetic Concepts, Inc. (KCI) will sponsor a CME-accredited panel discussion, “The Role of NPWT in the Team Approach to Limb Salvage: Case Studies,” at the 3rd Annual Georgetown Diabetic Limb Salvage conference September 24-26.

19 Sep 2009

New ultra-thin adhesives introduced by Avery Dennison Specialty Tape Division

Avery Dennison Specialty Tape Division, an innovative leader in adhesive materials for the medical sector, introduced two new ultra-thin adhesives and a hydrocolloid and adhesive technology solution at MEDTEC China this week.

19 Sep 2009

Wound Management Technologies acquires BioPharma

Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today that it has completed the acquisition of BioPharma Management Technologies, Inc., a privately held biotechnology company with a platform of proprietary and patented technologies for topical pain management and resorbable orthoses.

18 Sep 2009

National Institute for Health Research funds for wound care research

The University of York's Department of Health Sciences and NHS Leeds Community Healthcare have been awarded a £1.75m grant from the National Institute for Health Research to carry out a study into complex wounds.

17 Sep 2009

FDA provides 510(k) marketing clearance for the FlexStent Biliary Self Expanding Stent System

Flexible Stenting Solutions Inc. (“FSS”), a leading developer of next generation peripheral arterial and biliary stents, received 510(k) clearance for the FlexStent® Biliary Self Expanding Stent System.

17 Sep 2009

Clinical trial focuses on healing diabetic foot ulcers with stem cells

Fortis Healthcare, one of India's leading private hospital groups, has announced it will broaden inclusion criteria for its upcoming diabetic foot clinical trial. The study will use stem cells derived from peripheral blood to treat critical limb ischemia (diabetic foot).

17 Sep 2009

ULURU reports Altrazeal clinical trial results

ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either Altrazeal(TM) or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing.

17 Sep 2009

OCLS' partnership with V&M Industries to market Microcyn-based skin and wound care products

Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat infections in chronic and acute wounds, announced today it has entered into a new strategic partnership with V&M Industries, Inc. for non-exclusive rights to market Microcyn-based skin and wound care over-the-counter products in the United States and Canada while providing Oculus with a significant percentage of those revenues.

16 Sep 2009

Genetically removing the osteopontin protein prevents lung diseases

In a development that could lead to a novel approach to the treatment of a devastating lung disease, biochemists at The University of Texas Health Science Center at Houston report they are the first to link the osteopontin (OPN) protein to chronic obstructive pulmonary disease (COPD).

16 Sep 2009

Today's Op-Ed selections: Medicare, Medicaid and the Constitution

My patient had just been the recipient of a rare and highly valued medical commodity, a treatment that is as quantifiable in its effects as the milligrams of a medication or the number of stitches in a wound: Time (Daphne Miller, 9/15).

16 Sep 2009

New hydrogel mats extends anti-infection protection

Treatment of hospital-related infections in the U.S. costs up to $11 billion a year and about half of those infections are related to medical devices implanted in patients. Until now, efforts to control drug-resistant biofilms on such devices have been largely unsuccessful.

15 Sep 2009

NYSDOH blocks U.S.-Egypt study of ozone-based medical therapies for diabetic skin ulcers

A study exploring the healing of diabetic skin ulcers using topical oxygen/ozone gas mixtures could not proceed to completion and was now abandoned, according to Ozonics International, LLC, a veteran-owned biotechnology company engaged in the research and development of ozone-based medical therapies.

15 Sep 2009

HemCon Medical Technologies and Zimmer Dental sign distribution agreement

HemCon Medical Technologies, Inc. (“HemCon”), a leading developer of advanced medical products, is proud to announce the signing of an exclusive global distribution agreement with Zimmer Dental Inc., a leading provider of dental oral rehabilitation products and a subsidiary of Zimmer Holdings, Inc.

15 Sep 2009

Cardium's Gene Activated Matrix technology demonstrates benefits in periodontal tissue regeneration

Cardium Therapeutics (NYSE Amex: CXM) today reported on preclinical findings published in the scientific journal, Gene Therapy, demonstrating that Cardium's Gene Activated Matrix(TM) or GAM(TM) technology accelerates periodontal tissue regeneration of oral implant-supporting wounds.

15 Sep 2009

Wake Pharma to present clinical evidence in the treatment of wounds using Wound-Be-Gone at SAWC

Wake Pharma US announced today that clinical evidence in the treatment of wounds using Wound-Be-Gone® will be presented at the fall Society for Advance Wound Care Conference. The SAWC is being held in Washington, DC from September 16-18, 2009. The clinical evidence and data will be presented through posters on display during the meeting.

15 Sep 2009

Researchers study planaria's regeneration process

Amputations trigger a molecular response that determines if a head or tail will be regrown in planaria, a flatworm commonly studied for its regenerative capabilities. Until now, no molecular connection between wounding and the decision to regenerate either a head or tail in planaria had been identified.

15 Sep 2009

Misonix receives donation from anonoymous patient to buy SonicOne ultrasonic wound care system

Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has announced that a patient, who wishes to remain anonymous, donated the majority of the funds necessary for Christus St. Vincent Medical Center, Santa Fe, NM, to purchase a SonicOne(R) Ultrasonic Wound Cleansing and Debridement System. The System was shipped and installed during the second half of August 2009.

15 Sep 2009